Loading...
XLONPYC
Market cap1mUSD
Dec 24, Last price  
0.78GBP
1D
0.00%
1Q
11.11%
Jan 2017
-61.54%
Name

Physiomics PLC

Chart & Performance

D1W1MN
XLON:PYC chart
P/E
—
P/S
289.90
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.49%
Rev. gr., 5y
-7.05%
Revenues
543k
-9.06%
205,000113,000216,00091,000460,000153,00053,000135,306240,000267,903235,486297,120270,465512,899783,101799,055702,314830,266597,354543,250
Net income
-609k
L+27.68%
-382,000-480,000-193,000-434,00025,000-368,000-645,000-539,577-500,571-425,621-357,656-378,697-400,526-183,341-104,040-64,423-215,827-253,137-477,257-609,352
CFO
-548k
L+106.95%
-428,000-273,000-387,000-123,00026,000-434,000-643,000-551,772-524,487-351,507-392,651-346,869-437,274-169,797-143,772-115,691-32,496-349,251-264,863-548,133
Earnings
Mar 05, 2025

Profile

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.
URL
https://www.physiomics.co.uk/
IPO date
Dec 20, 2004
Employees
8
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
543
-9.06%
597
-28.05%
830
18.22%
Cost of revenue
1,232
1,190
1,270
Unusual Expense (Income)
NOPBT
(689)
(593)
(440)
NOPBT Margin
Operating Taxes
(59)
(95)
(106)
Tax Rate
NOPAT
(629)
(498)
(334)
Net income
(609)
27.68%
(477)
88.54%
(253)
17.29%
Dividends
Dividend yield
Proceeds from repurchase of equity
380
3
BB yield
-23.42%
-0.10%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(191)
(417)
(688)
Cash flow
Cash from operating activities
(548)
(265)
(349)
CAPEX
(17)
(7)
(9)
Cash from investing activities
(15)
(6)
(9)
Cash from financing activities
338
3
FCF
(628)
6
(828)
Balance
Cash
191
417
688
Long term investments
180
395
Excess cash
164
387
647
Stockholders' equity
(5,840)
(5,405)
(4,962)
Invested Capital
6,122
5,906
5,918
ROIC
ROCE
EV
Common stock shares outstanding
135,368
97,425
97,373
Price
0.01
23.08%
0.01
-66.95%
0.03
-53.91%
Market cap
1,624
71.01%
950
-66.93%
2,873
-53.79%
EV
1,433
533
2,184
EBITDA
(680)
(582)
(428)
EV/EBITDA
Interest
33
Interest/NOPBT